The estimated Net Worth of Mark Christopher Murray is at least $312 millier dollars as of 8 March 2024. Mr. Murray owns over 597 units of Avantor stock worth over $312,156 and over the last 5 years he sold AVTR stock worth over $0. In addition, he makes $0 as Executive Vice President of the Biomaterials and Advanced Technologies Platform at Avantor.
Sign up
Mr. Murray AVTR stock SEC Form 4 insiders trading
Mark has made over 3 trades of the Avantor stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 597 units of AVTR stock worth $93,389 on 8 March 2024.
The largest trade he's ever made was buying 1,200 units of Avantor stock on 28 February 2023 worth over $140,580. On average, Mark trades about 234 units every 31 days since 2020. As of 8 March 2024 he still owns at least 11,600 units of Avantor stock.
You can see the complete history of Mr. Murray stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Murray biography
Mark Murray serves as Executive Vice President of the Biomaterials and Advanced Technologies Platform of the Company. Mr. Mark Murray is our Executive Vice President, Biomaterials and Advanced Technologies, a position he has held since January 2020. Prior to joining us, Mr. Murray spent 13 years at Celanese, a global chemicals manufacturer, in a number of leadership positions including, most recently, Vice President of Global Sales for its material solutions business as well as leader of its global emulsions and ethylene vinyl acetate performance polymers businesses..
How old is Mark Murray?
Mark Murray is 49, he's been the Executive Vice President of the Biomaterials and Advanced Technologies Platform of Avantor since 2020. There are 23 older and 8 younger executives at Avantor. The oldest executive at Avantor Inc. is Rajiv Gupta, 74, who is the Chairman of the Board.
What's Mark Murray's mailing address?
Mark's mailing address filed with the SEC is 222 W. LAS COLINAS BLVD, STE 900N, IRVING, TX, 75039.
Insiders trading at Avantor
Over the last 5 years, insiders at Avantor have traded over $3,149,576,044 worth of Avantor stock and bought 27,800 units worth $584,024 . The most active insiders traders include Mountain Investments Iii, L..., Jo Natauri et Sachs & Co. Llc Stone Bridg.... On average, Avantor executives and independent directors trade stock every 21 days with the average trade being worth of $48,107,115. The most recent stock trade was executed by Steven W Eck on 5 September 2024, trading 3,525 units of AVTR stock currently worth $88,337.
What does Avantor do?
based in center valley, pa (usa), avantor performance materials manufactures and markets high-performance chemistries and materials around the world under several respected brand names, including the j.t.baker®, macron fine chemicals™, rankem™, benesphera™, and poch™ brands. avantor products are used in a wide range of industries. our life sciences solutions are used in pharmaceutical production, laboratory research for academic, industry and quality control, and in medical lab testing. our electronics solutions are used in the manufacturing of semiconductors. for additional information please visit www.avantormaterials.com
What does Avantor's logo look like?
Complete history of Mr. Murray stock trades at Celanese Corp et Avantor
Avantor executives and stock owners
Avantor executives and other stock owners filed with the SEC include:
-
Michael Stubblefield,
President, Chief Executive Officer, Director -
Thomas Szlosek,
Chief Financial Officer, Executive Vice President -
Michael Stubblefield,
Pres, CEO & Director -
Gerard Brophy,
Executive Vice President - Biopharma Production -
Devashish Ohri,
Executive Vice President - AMEA -
Frederic Vanderhaegen,
Executive Vice President - Americas and Europe -
Thomas A. Szlosek,
Exec. VP & CFO -
Frederic Vanderhaegen,
Exec. VP of Americas & Europe -
Dr. Gerald Brophy Ph.D.,
Exec. VP of Biopharma Production -
Michael Wondrasch,
Exec. VP & Chief Information Officer -
Rajiv Gupta,
Chairman of the Board -
Jonathan Peacock,
Independent Director -
Christi Shaw,
Independent Director -
Rakesh Sachdev,
Independent Director -
Juan Andres,
Independent Director -
Gregory Summe,
Independent Director -
Michael Severino,
Independent Director -
Jo Natauri,
Director -
Andre Moura,
Director -
Matthew Holt,
Director -
Steven Eck,
Senior Vice President, Chief Accounting Officer -
Mark Murray,
Executive Vice President of the Biomaterials and Advanced Technologies Platform -
Sven Henrichwark,
Executive Vice President of APAC -
Tanya Foxe,
Executive Vice President - Global Operations and Supply Chain -
Christophe Couturier,
Executive Vice President - Services, Strategy and Business Transformation -
James Bramwell,
Executive Vice President - Strategic Partners -
Justin Miller,
Executive Vice President, General Counsel, Secretary -
Michael Wondrasch,
Executive Vice President, Chief Information Officer -
Eric McAllister,
Chief Human Resource Officer, Executive Vice President -
Allison K. Hosak,
Sr. VP of Global Communications & Brand -
Justin M. Miller Esq.,
Exec. VP, Gen. Counsel & Sec. -
Tommy J. Thomas CPA,
VP of Investor Relations -
Steven W. Eck,
Sr. VP, Corp. Controller & Chief Accounting Officer -
Sheri Lewis,
Exec. VP, Global Operations & Supply Chain -
Lan Kang,
Director -
John Carethers,
Director -
Sachs & Co. Llc Stone Bridg...,
-
Sachs & Co. Llc Stone Bridg...,
-
Sheri Lewis,
EVP, Global Ops & Supply Chain -
Mountain Investments Iii, L...,
-
Mala Murthy,
Director -
Brittany Hankamer,
EVP, Chief HR Officer -
Randy Lee Stone,
EVP, Laboratory Solutions -
Corey Walker,
President Laboratory Solutions -
Ashish Kulkarni,
See Remarks -
Sachs & Co. Llcgoldman Sach...,
-
Meghan Henson,
EVP, Chief HR Officer -
Thomas Connolly,
Director -
Joseph R Massaro,
Director -
Kitty Sahin,
EVP, Strategy&Corp Development -
Claudius Sokenu,
EVP, Chief Legal & Compliance -
R. Brent Jones,
EVP, Chief Financial Officer -
Benoit Gourdier,
EVP, Biopharma Production